Short answer
GRAIL, Inc. (GRAL) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $36M (up 26.3% year over year) with net income of −$89M.
Q3 2025 key financials · XBRL
- Revenue
- $36M
- +26.3% YoY · +1.8% QoQ
- Net income
- −$89M
- +29.2% YoY · +21.9% QoQ
- Operating margin
- -346.2%
- EPS (diluted)
- −$2.45
- +30.0% YoY · +23.0% QoQ
Source: XBRL data from the GRAIL, Inc. (GRAL) Q3 2025 10-Q on SEC EDGAR. USD.
GRAIL, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Samsung Investment closing uncertainty due to pending CFIUS regulatory approval and negotiation of Korea-focused collaboration agreements, affecting expected $110M proceeds
- Updated risk: FDA LDT regulation vacated by court in March 2025, creating uncertainty in marketing authorization process and potential need to modify Galleri test configurations
- Regulatory risk: FDA may require additional clinical data delaying or narrowing Galleri PMA approval, impacting commercialization and reimbursement timelines
- Operational risk: Post-Dec 2024 updated Galleri test version faces increased turnaround times, re-processing costs, and sample failures, possibly harming reputation and revenue
- Financial risk: Increased international exposure, including suppliers in China, Mexico, Europe, with risks from tariffs, trade restrictions, currency fluctuations, and geopolitical instability
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other GRAIL, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.